CTLA4 and neoplasm: Furthermore, tumor-intrinsic YTHDF1 deficiency demonstrated synergistic effects with anti-CTLA-4 or anti-PD-L1 antibodies, leading to reduced tumor volume and extended overall survival in mice bearing B16/F10 cells [122].